226 related articles for article (PubMed ID: 30839416)
21. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T;
Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500
[TBL] [Abstract][Full Text] [Related]
22. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
Asrani S; Robin AL; Serle JB; Lewis RA; Usner DW; Kopczynski CC; Heah T;
Am J Ophthalmol; 2019 Nov; 207():248-257. PubMed ID: 31229466
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study.
Nakakura S; Kanamori A; Fukuma Y; Wakabayashi S; Nagata Y; Adachi M
BMJ Open; 2021 Jan; 11(1):e040301. PubMed ID: 33514572
[TBL] [Abstract][Full Text] [Related]
25. A Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of MGV354 for Ocular Hypertension or Glaucoma.
Stacy R; Huttner K; Watts J; Peace J; Wirta D; Walters T; Sall K; Seaman J; Ni X; Prasanna G; Mogi M; Adams C; Yan JH; Wald M; He Y; Newton R; Kolega R; Grosskreutz C
Am J Ophthalmol; 2018 Aug; 192():113-123. PubMed ID: 29802818
[TBL] [Abstract][Full Text] [Related]
26. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
[TBL] [Abstract][Full Text] [Related]
27. A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma.
Myers JS; Sall KN; DuBiner H; Slomowitz N; McVicar W; Rich CC; Baumgartner RA
J Ocul Pharmacol Ther; 2016 Oct; 32(8):555-562. PubMed ID: 27002298
[TBL] [Abstract][Full Text] [Related]
28. Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.
Ferro Desideri L; Cutolo CA; Barra F; Ferrero S; Traverso CE
Drugs Today (Barc); 2019 Jun; 55(6):377-384. PubMed ID: 31250842
[TBL] [Abstract][Full Text] [Related]
29. 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial.
Weinreb RN; Bacharach J; Fechtner RD; Kahook MY; Wirta D; Burmaster S; Meng X; Hubatsch DA
Ophthalmology; 2019 Aug; 126(8):1095-1104. PubMed ID: 30403988
[TBL] [Abstract][Full Text] [Related]
30. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
31. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.
Camras CB; Sheu WP;
J Glaucoma; 2005 Apr; 14(2):161-7. PubMed ID: 15741820
[TBL] [Abstract][Full Text] [Related]
32. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
Susanna R; Sheu WP;
Clin Ther; 2004 May; 26(5):755-68. PubMed ID: 15220019
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
[TBL] [Abstract][Full Text] [Related]
34. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
[TBL] [Abstract][Full Text] [Related]
35. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
36. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
38. Randomized, Controlled, Phase 3 Trials of Carteolol/Latanoprost Fixed Combination in Primary Open-Angle Glaucoma or Ocular Hypertension.
Yamamoto T; Ikegami T; Ishikawa Y; Kikuchi S;
Am J Ophthalmol; 2016 Nov; 171():35-46. PubMed ID: 27565224
[TBL] [Abstract][Full Text] [Related]
39. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
[TBL] [Abstract][Full Text] [Related]
40. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
